Why download this playbook?

Clinical Trial Agreement delays often surface late, but affect start-up early.

For emerging biotech teams, the impact can be significant:

  • delayed site activation
  • slower budget finalization
  • less predictable timelines
  • increased cross-functional friction
  • greater complexity as studies expand beyond the US

This playbook explains where delays come from and what organizations can do to improve speed, predictability, and execution discipline.

Who this is for

For biotech teams preparing for first ex-US studies, scaling site activation, or dealing with delays in contract execution.

What’s inside

  • Why CTA execution has become a strategic study start-up issue
  • Why the US remains highly variable despite market maturity
  • What changes when biotech teams expand beyond the US
  • What Europe’s contracting landscape reveals about delay and opportunity
  • Lessons from Germany, France, the Netherlands, and Poland
  • The 8 root causes of CTA delay across regions
  • The 7 levers of faster, more predictable CTA execution
  • Practical steps biotech teams can take now

Be the first to hear when registration opens >> Follow us on LinkedIn